Astellas Pharma Global Development, Inc.

This trial tested an experimental drug called ASP1570 in adults with advanced solid tumors that had spread or could not be removed by surgery. The drug aims to help the body's immune T-cells attack tumors that have become resistant. The study was in two parts: first to find a saf…

This early-phase trial tested ASP1012, a virus engineered to infect and kill cancer cells while making them visible to the immune system. It was given alone or with the immunotherapy pembrolizumab to 15 adults with advanced solid tumors. The main goals were to check safety and fi…

This early-stage study tested a new oral drug, ASP5502, for primary Sjögren's syndrome, an autoimmune condition causing dry eyes and mouth. It involved 116 healthy adults and patients to check safety and how the body processes the drug. The study was terminated, but results may g…

This study tested an experimental drug called enfortumab vedotin, alone or with other cancer drugs, in people with advanced bladder or urinary tract cancer. The goal was to see if the drug could shrink tumors and control the disease. The trial included 348 participants but was te…

This study tested a drug called gilteritinib, which targets a specific genetic change in leukemia cells, combined with standard chemotherapy in children and young adults (ages 6 months to 21 years) whose acute myeloid leukemia (AML) had returned or not responded to treatment. The…

This early-phase trial tested enfortumab vedotin, a drug placed directly into the bladder via a catheter, in 37 people with a type of bladder cancer that did not respond to standard BCG therapy. The main goals were to check safety and side effects, and to see if the drug could he…

This early-stage study tested a new type of CAR-T cell therapy (ASP2802) for people with B-cell lymphoma that came back or stopped responding to treatment. The therapy uses a person's own immune cells, modified to better fight cancer, plus a booster protein. The study was termina…

This early-phase trial tested a new drug called ASP2074 in 23 adults with advanced solid tumors that had spread or couldn't be removed by surgery. The goal was to find a safe dose and check for side effects. The study was terminated early, so results are limited.